Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17721195rdf:typepubmed:Citationlld:pubmed
pubmed-article:17721195lifeskim:mentionsumls-concept:C1261473lld:lifeskim
pubmed-article:17721195lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:17721195lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:17721195lifeskim:mentionsumls-concept:C1556084lld:lifeskim
pubmed-article:17721195lifeskim:mentionsumls-concept:C0439849lld:lifeskim
pubmed-article:17721195lifeskim:mentionsumls-concept:C1275282lld:lifeskim
pubmed-article:17721195lifeskim:mentionsumls-concept:C1710026lld:lifeskim
pubmed-article:17721195lifeskim:mentionsumls-concept:C1513380lld:lifeskim
pubmed-article:17721195lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:17721195lifeskim:mentionsumls-concept:C2827424lld:lifeskim
pubmed-article:17721195lifeskim:mentionsumls-concept:C0205549lld:lifeskim
pubmed-article:17721195pubmed:issue9lld:pubmed
pubmed-article:17721195pubmed:dateCreated2007-8-27lld:pubmed
pubmed-article:17721195pubmed:abstractTextLow-grade fibromyxoid sarcomas (LGFMS) bear either the t(7,16) (q32-34;p11) or t(11,16) (p11;p11) translocations, resulting in FUS-CREB3L2 or FUS-CREB3L1 fusions, respectively. Heretofore, fusion transcripts were mainly detected in frozen tissues, using reverse transcription-polymerase chain reaction. In this study, we aimed to develop a reliable method to detect these in paraffin-embedded tissues, and to examine the clinicopathologic characteristics of a series of translocation-positive LGFMS. Sixty-three neoplasms with typical morphologic features of LGFMS and 66 non-LGFMS tumors selected for their resemblance to LGFMS (LGFMS-like tumors) were examined. RNA of sufficient quality could be extracted from 111/129 (86%) cases (59 LGFMS, 52 non-LGFMS). Of all, 48/59 (sensitivity, 81%) LGFMS contained detectable transcripts (45 FUS-CREB3L2, 3 FUS-CREB3L1). Most relevant clinicopathologic features of fusion-positive LGFMS included predominance in lower extremities (22/48; thigh: 13/48), deep situation (46/48), and occasional presence of unusual histologic features, for example, hypercellular areas (16/48), foci of epithelioid cells (13/48), and giant rosettes (6/48). Most tumors expressed EMA (41/45), at least focally, CD99 (38/41) and bcl-2 (36/41) while being essentially negative for CD34 (2/45), mdm2 (1/41), smooth muscle actin (1/45), S100 protein (0/46), desmin (0/44), h-caldesmon (0/42), keratins (0/44), and CD117 (0/40). Eleven presumed LGFMS were fusion negative. Of all, 7/52 non-LGMFS neoplasms contained FUS-CREB3L2 transcripts, of which 4 had been diagnosed as sclerosing epithelioid fibrosarcoma. In conclusion, FUS-CREB3L1/L2 fusion transcripts can be detected in paraffin-embedded LGFMS in a sensitive manner, using reverse transcription-polymerase chain reaction. Most fusion-positive LGFMS are EMA-positive and CD34/S100/smooth muscle actin negative. The presence of epithelioid cells and fusion transcripts in both LGFMS and a subset of sclerosing epithelioid fibrosarcoma suggest that these neoplasms might be related.lld:pubmed
pubmed-article:17721195pubmed:languageenglld:pubmed
pubmed-article:17721195pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17721195pubmed:citationSubsetIMlld:pubmed
pubmed-article:17721195pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17721195pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17721195pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17721195pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17721195pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17721195pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17721195pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17721195pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17721195pubmed:statusMEDLINElld:pubmed
pubmed-article:17721195pubmed:monthSeplld:pubmed
pubmed-article:17721195pubmed:issn0147-5185lld:pubmed
pubmed-article:17721195pubmed:authorpubmed-author:Terrier-Lacom...lld:pubmed
pubmed-article:17721195pubmed:authorpubmed-author:CoindreJean-M...lld:pubmed
pubmed-article:17721195pubmed:authorpubmed-author:BenhattarJean...lld:pubmed
pubmed-article:17721195pubmed:authorpubmed-author:GuillouLouisLlld:pubmed
pubmed-article:17721195pubmed:authorpubmed-author:GenglerCarole...lld:pubmed
pubmed-article:17721195pubmed:authorpubmed-author:PedeutourFlor...lld:pubmed
pubmed-article:17721195pubmed:authorpubmed-author:TerrierPhilip...lld:pubmed
pubmed-article:17721195pubmed:authorpubmed-author:MarquèsBernar...lld:pubmed
pubmed-article:17721195pubmed:authorpubmed-author:CollinFrançoi...lld:pubmed
pubmed-article:17721195pubmed:authorpubmed-author:KeslairFrédér...lld:pubmed
pubmed-article:17721195pubmed:authorpubmed-author:GallagherGabr...lld:pubmed
pubmed-article:17721195pubmed:authorpubmed-author:Ranchère-Vinc...lld:pubmed
pubmed-article:17721195pubmed:authorpubmed-author:LerouxAgnèsAlld:pubmed
pubmed-article:17721195pubmed:authorpubmed-author:Aubain...lld:pubmed
pubmed-article:17721195pubmed:issnTypePrintlld:pubmed
pubmed-article:17721195pubmed:volume31lld:pubmed
pubmed-article:17721195pubmed:ownerNLMlld:pubmed
pubmed-article:17721195pubmed:authorsCompleteYlld:pubmed
pubmed-article:17721195pubmed:pagination1387-402lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:meshHeadingpubmed-meshheading:17721195...lld:pubmed
pubmed-article:17721195pubmed:year2007lld:pubmed
pubmed-article:17721195pubmed:articleTitleTranslocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group.lld:pubmed
pubmed-article:17721195pubmed:affiliationUniversity Institute of Pathology, Lausanne, Switzerland. louis.guillou@chuv.chlld:pubmed
pubmed-article:17721195pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17721195pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:17721195pubmed:publicationTypeEvaluation Studieslld:pubmed
entrez-gene:2521entrezgene:pubmedpubmed-article:17721195lld:entrezgene
entrez-gene:64764entrezgene:pubmedpubmed-article:17721195lld:entrezgene
entrez-gene:90993entrezgene:pubmedpubmed-article:17721195lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:17721195lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:17721195lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:17721195lld:entrezgene
lhgdn:association:21037lhgdn:found_inpubmed-article:17721195lld:lhgdn
lhgdn:association:21042lhgdn:found_inpubmed-article:17721195lld:lhgdn
lhgdn:association:57060lhgdn:found_inpubmed-article:17721195lld:lhgdn
lhgdn:association:57061lhgdn:found_inpubmed-article:17721195lld:lhgdn
lhgdn:association:61782lhgdn:found_inpubmed-article:17721195lld:lhgdn
lhgdn:association:61784lhgdn:found_inpubmed-article:17721195lld:lhgdn
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17721195lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17721195lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17721195lld:pubmed